A study to determine risk of UTIs and genital infections associated with SGLT2 inhibitors in diabetic patients by age and sex using representative nationwide sample data from Korea
Latest Information Update: 11 Aug 2021
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 11 Aug 2021 New trial record
- 01 Aug 2021 Results published in the Maturitas